Scynexis Inc (SCYX): R&D Expense
$22.28M
Year ended 2025-12-31
$26.24M
Trailing 12 months to 2026-06-30
-6.5%
3-year compound annual growth
-9.4%
5-year compound annual growth
+3.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $22.28M | -15.6% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $26.41M | -14.6% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $30.93M | +13.5% | 2025-03-12, From 2023-01-01 |
| 2022-12-31 | $27.26M | +14.7% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $23.77M | -34.9% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $36.52M | -4.9% | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | $38.39M | +78.1% | 2021-03-29, From 2019-01-01 |
| 2018-12-31 | $21.56M | +17.6% | 2020-03-11, From 2018-01-01 |
| 2017-12-31 | $18.33M | -8.7% | 2019-03-14, From 2017-01-01 |
| 2016-12-31 | $20.08M | +22.1% | 2018-03-13, From 2016-01-01 |
| 2015-12-31 | $16.44M | +98.4% | 2017-03-13, From 2015-01-01 |
| 2014-12-31 | $8.29M | +89.9% | 2017-03-13, From 2014-01-01 |
| 2013-12-31 | $4.36M | n/a | 2015-03-30, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Scynexis Inc (SCYX) | 2025-12-31 | $22.28M | -15.6% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $6.31M | -29.3% |
| Evofem Biosciences, Inc. (EVFM) | 2024-12-31 | $1.84M | -37.2% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $22.80M | +28.1% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $141.83M | -6.3% |
| Alumis Inc. (ALMS) | 2025-12-31 | $386.00M | +45.4% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $142.27M | +13.5% |
| uniQure N.V. (QURE) | 2025-12-31 | $140.67M | -2.2% |
| Celularity Inc (CELU) | 2025-12-31 | $15.03M | -13.6% |
Compare SCYX, CASIF, EVFM, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗